Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Broich

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Biochemical Pharmacology|November 27, 2013
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020Harald Hampel, Simone Lista, Stefan J Teipel, et al.
Dialogues in Clinical Neuroscience|October 23, 2019
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
Harald Hampel, Andrea Vergallo, Mohammad Afshar, et al.
Lancet (London, England)|April 25, 2006
Mild cognitive impairmentSerge Gauthier, Barry Reisberg, Michael Zaudig, et al.
Pharmacological Research|February 20, 2018
Precision pharmacology for Alzheimer's diseaseHarald Hampel, Andrea Vergallo, Lisi Flores Aguilar, et al.
European Archives of Psychiatry and Clinical Neuroscience|October 25, 2014
Risk of dementia in elderly patients with the use of proton pump inhibitorsBritta Haenisch, Klaus von Holt, Birgitt Wiese, et al.
Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 2, 2013
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task ForceBruno Vellas, Maria C Carrillo, Cristina Sampaio, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive DeclineSimone Lista, Jose L Molinuevo, Enrica Cavedo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
The Journal of Clinical Psychiatry|August 28, 2010
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statementRoger E Meyer, Carl Salzman, Eric A Youngstrom, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Biochemical Pharmacology|November 27, 2013
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020Harald Hampel, Simone Lista, Stefan J Teipel, et al.
Dialogues in Clinical Neuroscience|October 23, 2019
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
Harald Hampel, Andrea Vergallo, Mohammad Afshar, et al.
Lancet (London, England)|April 25, 2006
Mild cognitive impairmentSerge Gauthier, Barry Reisberg, Michael Zaudig, et al.
Pharmacological Research|February 20, 2018
Precision pharmacology for Alzheimer's diseaseHarald Hampel, Andrea Vergallo, Lisi Flores Aguilar, et al.
European Archives of Psychiatry and Clinical Neuroscience|October 25, 2014
Risk of dementia in elderly patients with the use of proton pump inhibitorsBritta Haenisch, Klaus von Holt, Birgitt Wiese, et al.
Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 2, 2013
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task ForceBruno Vellas, Maria C Carrillo, Cristina Sampaio, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive DeclineSimone Lista, Jose L Molinuevo, Enrica Cavedo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
The Journal of Clinical Psychiatry|August 28, 2010
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statementRoger E Meyer, Carl Salzman, Eric A Youngstrom, et al.
Pageof 10